- Expression and Clinicopathological Significances of lncRNAs: Could ARA and ZEB2NAT be the Potential Breast Cancer-Related Biomarkers?
-
Asaad Azarnezhad,1,*
1. Kurdistan University of Medical Sciences, Sanandaj, Iran.
- Introduction: Pieces of evidence have shown that a significant proportion of cancer-prone factors are not attributed to alterations in protein-coding sequences. Adriamycin resistance-related (ARA) and natural antisense of ZEB2 (ZEB2NAT) long non-coding RNAs (lncRNAs) have been indicated with oncogenic properties by regulating various signaling pathways and epithelial-to-mesenchymal transition (EMT), which may have diagnostic and prognostic potential as a novel group of biomarkers. The current study aimed to evaluate the expression status of ARA and ZEB2NAT lncRNAs and their clinicopathological significance in a population with breast cancer (BC).
- Methods: Total RNA was extracted from 60 tumor samples and their normal adjacent tissues (NATs). The lncRNA expressions were measured using quantitative reverse transcription PCR (RT-qPCR) and statistical analyses were performed by SPSS version 25.
- Results: Our data showed a significant upregulation of ARA and ZEB2NAT lncRNAs in tumor tissues compared to NATs (p <0.001; p = 0.021, respectively). ARA and ZEB2NAT expression were observed to be significantly associated with tumor grade, nuclear grade, tumor stages, and lymph node metastasis (p <0.05). Additionally, ARA expression was significantly correlated with breastfeeding status (p = 0.027).
- Conclusion: Our data revealed that ARA and ZEB2NAT lncRNAs were overexpressed in BC. Furthermore, the selected lncRNAs were found to might be the potential biomarkers for BC diagnosis and prognosis. However, the findings of the current research are required to be replicated in other studies with larger sample sizes.
- Keywords: Breast cancer, long non-coding RNA, Biomarker, ARA, ZEB2NAT